Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932546 | 0.72 | KDM4E (0.46) | KDM4EALDH1A1CYP1A2CYP2C19BLM | |
| SCHEMBL29545868 | 0.72 | KDM4E (0.46) | KDM4EALDH1A1CYP1A2CYP2C19BLM | |
| Hydrochloric Acid SCHEMBL28868510 | 0.71 | KDM4E (0.44) | KDM4EALDH1A1CYP1A2CYP2C19BLM | |
| Hydrochloric Acid SCHEMBL30431695 | 0.71 | KDM4E (0.44) | KDM4EALDH1A1CYP1A2CYP2C19BLM | |
| Water SCHEMBL6479622 | 0.71 | KDM4E (0.44) | KDM4EALDH1A1CYP1A2CYP2C19BLM | |
| SCHEMBL5443522 | 0.65 | RPS6KA3 (0.60) | CASP6KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5442977 | 0.65 | KDM4E (0.60) | CASP6KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL5309140 | 0.65 | KDM4E (0.53) | CASP6KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31214551 | 0.64 | MAPT (0.62) | CASP6KDM4EALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3261597 | 0.64 | KDM4E (0.46) | CASP6KDM4EALDH1A1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010072807-A2 | INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE | FONDATION JEROME LEJEUNE (FR) | 2010-07-01 | — | — | WO | claimed |
| EP-0407888-B1 | Pyrimido[5,4-e]-as-triazine-5,7(6H,8H)-diones used to control undesirable plant growth | BASF AG (DE) | 1994-03-09 | — | — | EP | claimed |
| EP-0407888-A1 | Pyrimido[5,4-e]-as-triazine-5,7(6H,8H)-diones used to control undesirable plant growth | BASF Aktiengesellschaft (DE) | 1991-01-16 | — | — | EP | claimed |
| EP-4613274-A1 | SENOLYTIC COMPOUNDS | Freie Universität Berlin (DE) | 2025-09-10 | — | — | EP | disclosed |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| EP-4129282-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| EP-4129282-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2010514-B1 | 3-(PYRIDIN-2-YL)-[1,2,4]-TRIAZINES FOR USE AS FUNGICIDES | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-7737144-B2 | Pyrimido[5,4-e][1,2,4]triazine-5-7-diones, processes for preparing them and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-15 | — | — | US | disclosed |
| WO-2004065387-A1 | PYRIMIDO[5,4-E][1,2,4]TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004065387-A1 | PYRIMIDO[5,4-E][1,2,4]TRIAZINE-5,7-DIONES, METHODS FOR PRODUCING THE SAME AND THEIR USE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
| EP-0407888-B1 | Pyrimido[5,4-e]-as-triazine-5,7(6H,8H)-diones used to control undesirable plant growth | BASF AG (DE) | 1994-03-09 | — | — | EP | disclosed |
| EP-0407888-B1 | Pyrimido[5,4-e]-as-triazine-5,7(6H,8H)-diones used to control undesirable plant growth | BASF AG (DE) | 1994-03-09 | — | — | EP | disclosed |
| US-5069708-A | PRE-AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| US-5069708-A | PRE-AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| US-5069708-A | PRE-AND POSTEMERGENCE HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
| EP-0407888-A1 | Pyrimido[5,4-e]-as-triazine-5,7(6H,8H)-diones used to control undesirable plant growth | BASF Aktiengesellschaft (DE) | 1991-01-16 | — | — | EP | disclosed |
| EP-0407888-A1 | Pyrimido[5,4-e]-as-triazine-5,7(6H,8H)-diones used to control undesirable plant growth | BASF Aktiengesellschaft (DE) | 1991-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | APAF1 196/4885CASP6 281/4885KDM4E 2362/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | APAF1 3065/4885CASP6 1130/4885KDM4E 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.